Tolerx’s Partner Genentech Initiates Phase I Monoclonal Antibody Trial
Tolerx has announced that Genentech, a collaborator, has moved a modified version of TRX1, MTRX1011A, an anti-CD4 monoclonal antibody, into a Phase I clinical trial that has begun enrolling patients.
The clinical trial is evaluating the safety and tolerability of both single and multiple doses of MTRX1011A. The initiation of the Phase I clinical trial resulted in the realization of an additional milestone by Tolerx.
Under the terms of the collaboration agreement between Tolerx and Genentech, Tolerx realized milestones in the first quarter of 2008 upon selection of the antibody for further development within Genentech’s clinical pipeline and upon investigational new drug filing.
Douglas Ringler, president and CEO of Tolerx, said: “We are extremely pleased that our collaboration with Genentech has resulted in the continued advancement of the program, and we look forward to continued progress.”